Integra LifeSciences (NASDAQ:IART) Updates Q2 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its second quarter 2025 earnings guidance on Monday morning. The company provided EPS guidance of 0.400-0.450 for the period, compared to the consensus EPS estimate of 0.570. The company issued revenue guidance of $390.0 million-$400.0 million, compared to the consensus revenue estimate of $417.0 million. Integra LifeSciences also updated its FY 2025 guidance to 2.190-2.290 EPS.

Integra LifeSciences Stock Up 2.5 %

Shares of NASDAQ IART opened at $16.85 on Monday. Integra LifeSciences has a 12-month low of $14.45 and a 12-month high of $32.66. The stock has a market cap of $1.30 billion, a P/E ratio of -187.20, a PEG ratio of 0.73 and a beta of 1.27. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The business’s fifty day simple moving average is $19.94 and its 200-day simple moving average is $22.13.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter last year, the business posted $0.89 EPS. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. As a group, equities analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the subject of several recent analyst reports. Truist Financial decreased their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, April 11th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $22.71.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.